




RealRate

# PHARMACEUTICAL 2020

Zoetis Inc.  
Rank 200 of 358





RealRate

# PHARMACEUTICAL 2020

Zoetis Inc.  
Rank 200 of 358



The relative strengths and weaknesses of Zoetis Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Zoetis Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 84% points. The greatest weakness of Zoetis Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 133% points.

The company's Economic Capital Ratio, given in the ranking table, is 60%, being 24% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	4,748,000
Cost of Goods Sold	1,992,000
Intangible Assets	4,482,000
Liabilities, Current	1,806,000
Liabilities, Non-Current	6,340,000
Other Assets	375,000
Other Compr. Net Income	-97,000
Other Expenses	730,000
Other Liabilities	691,000
Other Net Income	57,000
Other Revenues	6,260,000
Property and Equipment	1,940,000
Research and Development	457,000
Selling, General and Administrative Expense	1,638,000

Output Variable	Value in 1000 USD
Assets	11,545,000
Liabilities	8,837,000
Expenses	4,817,000
Revenues	6,260,000
Stockholders Equity	2,708,000
Net Income	1,500,000
Comprehensive Net Income	1,451,500
Economic Capital Ratio	60%